Therapeutic strategies for catatonia in paraneoplastic encephalitis.

Department of Psychiatry, University of Muenster, Germany.
The World Journal of Biological Psychiatry (Impact Factor: 4.23). 08/2007; 9(3):236-40. DOI: 10.1080/15622970701459802
Source: PubMed

ABSTRACT This report is about a 40-year-old man suffering from fluctuating catatonia as main symptom of long-lasting paraneoplastic encephalitis caused by a testicular neoplasm. With recurrence of a neoplasm initially diagnosed as seminoma after a 7-year symptom-free interval the patient suddenly developed various neurological and psychopathological symptoms including seizures, autonomic dysregulation, continuous anterograde short-term amnesia and predominantly a long-lasting complex catatonic syndrome with on-off phenomena. Repeated MRI scans of the brain showed no pathology; brain FDG-PET scans indicated a hypometabolism of the frontal cortex and the left temporal lobe. Eventually a paraneoplastic encephalitis was diagnosed. Repeated resections of tumour recurrences and plasmapheresis moderately alleviated catatonic symptoms. Haloperidol and lorazepam effectively relieved catatonic symptoms in contrast to various atypical antipsychotic drugs and diazepam. A series of 12 electroconvulsive treatments (ECT) temporarily improved residual catatonic symptoms such as catalepsy, stupor and mutism. Further neoplasm recurrences, however, reinforced catatonia until the tumour was successfully treated and the patient fully recovered. This case report illustrates the potential but also the limitations of various therapeutic approaches in organic catatonia due to paraneoplastic encephalitis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a case of bilateral occipitotemporal and thalamic hypometabolism on FDG PET in a 19-year-old male patient who presented with altered mental status. He had a history of static encephalopathy and presented with visual hallucinations and decreased verbal output, sleep, and appetite 7 days after starting amoxicillin for otitis media. Extensive evaluation failed to demonstrate any infectious, inflammatory, autoimmune-mediated (including negative testing for NMDA receptor antibody), paraneoplastic, or toxic-metabolic etiology. Ultimately, he responded well to a benzodiazepine challenge and electroconvulsive therapy and was diagnosed with catatonia.
    Clinical nuclear medicine 04/2013; · 3.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the "level of evidence" criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized. J. Clin. Apheresis 28:145-284, 2013. © 2013 Wiley Periodicals, Inc.
    Journal of Clinical Apheresis 07/2013; 28(3):145-284. · 2.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer patients may develop paraneoplastic neurological conditions associated with autoantibodies directed against neural or neuromuscular tissues. These syndromes are frequently manifested in advance of the cancer presentation by several months or years necessitating a detailed and expensive investigation to search for the presence of a malignancy. In such cases additional assistance may be obtained by the early employment of whole body 18F flurodeoxyglucose positron emission tomography as a cancer screening imaging procedure for early cancer diagnosis and potential therapy. Effective therapy of the primary cancer consists the best current therapy for a given paraneoplastic syndrome. However, other forms of immune modulation, such as plasma exchange, intravenous gamma globulin, other immune therapies and symptomatic treatment for certain PNS may have additional benefit.
    Expert Review of Clinical Immunology 03/2014; · 3.34 Impact Factor


Available from
May 29, 2014